SCHEMBL20765237

SCHEMBL20765237

COc1cnc(-c2ccccc2)c2ncc(C(N)=O)nc12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.41
ADORA1 P30542 1/20 0.41
HSP90AA1 P07900 1/20 0.41
KMT2A Q03164 1/20 0.40
SIRT6 Q8N6T7 1/20 0.39
PARP1 P09874 2/20 0.39
ALDH1A1 P00352 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.38
RECQL P46063 1/20 0.38
TYMS P04818 1/20 0.38
NPC1 O15118 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
NEK2 P51955 1/20 0.37
DGAT1 O75907 1/20 0.37
SOAT1 P35610 1/20 0.37
MKNK1 Q9BUB5 2/20 0.36
MKNK2 Q9HBH9 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20765260 0.82 ACACA (0.43) ADORA1KMT2ASIRT6PARP1KDM4E
SCHEMBL20765238 0.80 ADORA1 (0.45) ADORA1KMT2AALDH1A1L3MBTL1KDM4E
SCHEMBL476267 0.76 CNR1 (0.62) CNR1ALDH1A1KDM4EDGAT1SOAT1
SCHEMBL20765251 0.74 IKBKB (0.40) KMT2ASIRT6PARP1ALDH1A1KDM4E
SCHEMBL25560072 0.74 ALDH1A1 (0.46) ADORA1HSP90AA1KMT2AALDH1A1L3MBTL1
SCHEMBL20765241 0.74 MKNK1 (0.56) NPC1MKNK1MKNK2
SCHEMBL22634431 0.72 GRM2 (0.38) SIRT6PARP1
SCHEMBL22634415 0.72 FYN (0.44) ADORA1PARP1MKNK1MKNK2
SCHEMBL22634407 0.72 GRM2 (0.42) SIRT6PARP1
SCHEMBL22634397 0.72 SQOR (0.42) ALDH1A1L3MBTL1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192899-B2 Quinoxaline derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2021-12-07 US claimed
US-20200354375-A1 QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2020-11-12 US claimed
CN-110944994-A Quinoxaline derivatives as adenosine receptor antagonists 默克专利股份公司 2020-03-31 CN claimed
US-11192899-B2 Quinoxaline derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2021-12-07 US disclosed
US-20200354375-A1 QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2020-11-12 US disclosed
EP-3672951-A1 QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS Merck Patent GmbH (DE) 2020-07-01 EP disclosed
CN-110944994-A Quinoxaline derivatives as adenosine receptor antagonists 默克专利股份公司 2020-03-31 CN disclosed
WO-2019038214-A1 QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2019-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354375-A1 QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2A, ADORA1, P2RY1 CNR1 137/4885ADORA1 2/4885HSP90AA1 3776/4885
US-11192899-B2 Quinoxaline derivatives as adenosine receptor antagonists ADORA2A, ADORA1, P2RY1 CNR1 137/4885ADORA1 2/4885HSP90AA1 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.